Hims & Hers made a controversial decision to stop selling a compounded version of Novo Nordisk’s obesity pill on its telehealth platform after facing scrutiny from health officials. The company had recently launched the cheaper alternative at $49 a month, which significantly undercut Novo Nordisk’s official pricing of $149 to $299 a month for the same medication.
Novo Nordisk, the pharmaceutical company behind the obesity pill, immediately raised concerns about the legality of Hims’ actions. Mass producing copies of a brand-name drug is typically only permitted when there is a shortage of the original medication. In this case, the availability of Novo Nordisk’s pill made Hims’ compounded version appear to be in violation of federal law.
The Food and Drug Administration (FDA) wasted no time in addressing the issue, announcing its intent to take “decisive steps” to prevent companies like Hims from marketing unapproved, compounded versions of GLP-1 drugs. Following the FDA’s statement, the Department of Health and Human Services (HHS) took further action by requesting an investigation into Hims by the Department of Justice.
The controversy surrounding Hims’ compounded obesity pill has sparked a debate about the ethics of mass producing alternative versions of brand-name drugs. The situation serves as a reminder of the importance of adhering to regulations and upholding the integrity of the pharmaceutical industry.
As the story continues to unfold, it is evident that the healthcare landscape is constantly evolving, with companies like Hims & Hers at the forefront of innovation. Stay tuned for updates on this developing story as more information becomes available.
